Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases
View Patent ↗Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
1. A method for inhibiting a humoral immune response in a subject comprising administering to the subject a pharmaceutical composition comprising an effective amount of an antibody directed against surface lymphotoxin (LT) ligand, and a pharmaceutically acceptable carrier, such that a humoral immune response is inhibited.
2. The method according to claim 1 , wherein the antibody directed against surface LT ligand is an antibody that binds to surface LT ligand without binding to secreted LTα.
3. The method according to claim 1 , wherein the antibody directed against surface LT ligand binds to LTβ.
4. The method according to claim 3 , wherein LTβ is human LTβ.
5. The method according to claim 1 , wherein the antibody directed against surface LT ligand functions as an LTβR blocking agent.
6. A method for inhibiting a humoral immune response by inhibiting LT-β receptor signaling without inhibiting TNF-R signaling in a subject comprising administering to a subject a pharmaceutical composition comprising an amount of an antibody directed against surface LT ligand, and a pharmaceutically acceptable carrier, such that a humoral immune response is inhibited by inhibiting LT-β receptor signaling without inhibiting TNF-R signaling.
7. The method according to claim 6 , wherein the antibody directed against surface LT ligand is an antibody that binds to surface LT ligand without binding to secreted LTα.
8. The method according to claim 6 , wherein the antibody directed against surface LT ligand binds to LTβ.
9. The method according to claim 8 , wherein LTβ is human LTβ.
10. The method according to claim 6 , wherein the antibody directed against surface LT ligand functions as an LTβR blocking agent.
11. A method for disrupting the association of immune complexes and B cell follicles in a subject comprising administering to the subject a pharmaceutical composition comprising an amount of an antibody directed against surface LT ligand, and pharmaceutically acceptable carrier, such that the association of immune complexes and B cell follicles is disrupted.
12. The method according to claim 11 , wherein the antibody directed against surface LT ligand is an antibody that binds to surface LT ligand without binding to secreted LTα.
13. The method according to claim 11 , wherein the antibody directed against surface LT ligand binds to LTβ.
14. The method according to claim 13 , wherein LTβ is human LTβ.
15. The method according to claim 11 , wherein the antibody directed against surface LT ligand functions as an LTβR blocking agent.
16. A method of inhibiting a humoral response in a subject suffering from a hypersensitivity response, comprising administering to the subject a pharmaceutical composition comprising an effective amount of an antibody directed against surface LT ligand, and a pharmaceutically acceptable carrier, such that a humoral response is inhibited.
17. The method according to claim 16 , wherein the antibody directed against surface LT ligand is an antibody that binds to surface LT ligand without binding to secreted LTα.
18. The method according to claim 16 , wherein the antibody directed against surface LT ligand binds to LTβ.
19. The method according to claim 18 , wherein LTβ is human LTβ.
20. The method according to claim 16 , wherein the antibody directed against surface LT ligand functions as an LTβR blocking agent.
21. The method of claim 16 , wherein the hypersensitivity response is a type I response.
22. The method of claim 16 , wherein the hypersensitivity response is a type II or type III response.
23. A method of inhibiting a humoral response associated with graft rejection in a subject comprising administering a pharmaceutical composition comprising an effective amount of an antibody directed against surface LT ligand, and a pharmaceutically acceptable carrier, such that the humoral immune response associated with graft rejection is inhibited.
24. The method according to claim 23 , wherein the antibody directed against surface LT ligand is an antibody that binds to surface LT ligand without binding to secreted LTα.
25. The method according to claim 23 , wherein the antibody directed against surface LT ligand binds to LTβ.
26. The method according to claim 25 , wherein LTβ is human LTβ.
27. The method according to claim 23 , wherein the antibody directed against surface LT ligand functions as an LTβR blocking agent.
28. A method for inhibiting a humoral immune response in a subject comprising administering a pharmaceutical composition comprising an antibody directed against surface LT ligand, and a pharmaceutically acceptable carrier, such that the humoral immune response is inhibited.
29. A method for inhibiting a humoral immune response by inhibiting LT-β receptor signaling without inhibiting TNF-R signaling in a subject comprising administering a pharmaceutical composition comprising an antibody directed against surface LT ligand, such that the humoral immune response is inhibited by inhibiting LT-β receptor signaling without inhibiting TNF-R signaling.